WASHINGTON – The Senate Judiciary Committee has scheduled a Nov. 30 hearing to discuss pricing policies for the Mylan Pharmaceuticals EpiPen epinephrine injector that led to a $465 million settlement with the government.
Judiciary Committee member Amy Klobuchar was among those who called for the hearing.
The hearing will also focus on the misclassification of EpiPen as a generic, a designation that Klobuchar and others said allowed the company to receive more money from the federal Medicaid program than it should have.
More from Star Tribune
More from Star Tribune
More from Star Tribune
More from Star Tribune
More from Star Tribune
More from Star Tribune
More from Star Tribune
More From Star Tribune
More From Business
Business
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
European Union leaders on Thursday debated a new ''European Competitiveness Deal'' aimed at helping the 27-nation bloc close the gap with Chinese and American rivals amid fears the region's industries will otherwise be left behind for good.
Business
Frustrated farmers are rebelling against EU rules. The far right is stoking the flames
Inside the barn on the flat fields of the northern Netherlands, Jos Ubels cradles a newborn Blonde d'Aquitaine calf, the latest addition to his herd of over 300 dairy cattle.
Business
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
World shares were mixed on Thursday after sinking technology stocks sent Wall Street lower again.
Business
European Union official urges G7 to step up air defense for Ukraine and expand Iran sanctions
The European Union's top diplomat urged Group of Seven foreign ministers on Thursday to take quick, concrete steps to provide more air defense systems to Ukraine, warning that continued delays could tilt the war in Moscow's favor.
Business
Nokia sees double-digit fall in January-March sales as weak market for 5G technology prevails
Wireless and fixed-network equipment maker Nokia on Thursday reported a smaller-than-expected profit and a double-digit fall in sales in the first quarter due to a market weakened by a lack of clients investing in 5G technology.
